Reports of suicide and self-injury linked to liraglutide, semaglutide, and tirzepatide from European drug safety data

Regulatory agencies have not confirmed a causal relationship between GLP-1 and GIP receptor agonists and suicidality.

• GLP-1 and GIP receptor agonists are increasingly used for type 2 diabetes and chronic weight management.
• Concerns about potential psychiatric adverse events are being raised as their use expands.
• Post-marketing monitoring is necessary due to the growing use of these medications for weight management.

Simplified